4/A: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., has sold 1,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp. (UTHR), reported a transaction involving the sale of 1,500 shares of common stock.
• The sale occurred on May 26, 2026, at a weighted average price of $575.9649 per share, with individual trades ranging from $575.51 to $576.50.
• This transaction was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.
• The plan is set to continue until the exercise of 1,734,410 stock options, which expire on March 17, 2027, or until December 31, 2026, whichever comes first.
• Following the transaction, Rothblatt beneficially owns 43,153 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine transaction under a pre-established trading plan by a key executive, rather than a significant strategic or financial event.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating adherence to established trading strategies and potentially mitigating insider trading concerns.
• The transaction was executed at a price range reflecting the current market value, with a weighted average price of $575.9649.

Negatives

• A reduction in the beneficial ownership of common stock by the CEO, which could be perceived negatively by the market, although it is part of a planned divestment.

Risks

• The 10b5-1 plan has an expiration date of December 31, 2026, or upon the exercise of all remaining options, introducing a time-bound element to the trading strategy.
• The stock options held by the reporting person expire on March 17, 2027, which may influence future trading decisions.

Future Outlook

The 10b5-1 trading plan is active and will continue until December 31, 2026, or until 1,734,410 stock options are exercised, whichever occurs first. The options themselves expire on March 17, 2027.

Management Comments

• The sale of stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person.
• The plan will continue until the exercise of 1,734,410 stock options, all of which expire on March 17, 2027, or December 31, 2026.

Industry Context

StockSavvy.ai notes that the use of 10b5-1 plans by executives is a common practice to diversify holdings and manage personal finances while adhering to insider trading regulations. This filing indicates a routine execution of such a plan within the biotechnology sector.

Stakeholder Impact

• Shareholders: The sale of shares by the CEO, while planned, may lead to short-term market perception shifts. However, the adherence to a 10b5-1 plan aims to mitigate concerns about insider trading.
• Employees: The transaction does not directly impact employee stock options or benefits but reflects the financial management of a senior leader.

Next Steps

• Continued execution of the 10b5-1 trading plan until its termination conditions are met.
• Potential exercise of remaining stock options before their expiration on March 17, 2027.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, 10b5-1 Plan, Stock Options, Common Stock, Securities Exchange Act, Beneficial Ownership, Martine Rothblatt